These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18277013)

  • 21. Celecoxib, a cyclooxygenase-2 inhibitor, prevents induction of liver preneoplastic lesions in rats.
    Márquez-Rosado L; Trejo-Solís MC; García-Cuéllar CM; Villa-Treviño S
    J Hepatol; 2005 Oct; 43(4):653-60. PubMed ID: 16023763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cyclooxygenase-2 inhibitor celecoxib and alveolar osteitis.
    Al-Sukhun J; Penttilä H
    J Ir Dent Assoc; 2011; 57(1):50-3. PubMed ID: 21413548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Celecoxib, a COX-2--specific inhibitor: the clinical data.
    Fort J
    Am J Orthop (Belle Mead NJ); 1999 Mar; 28(3 Suppl):13-8. PubMed ID: 10193998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Celecoxib and cardiovascular risks.
    Brophy JM
    Expert Opin Drug Saf; 2005 Nov; 4(6):1005-15. PubMed ID: 16255660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
    Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
    Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS; Liu DS; Dai CW; Li RJ
    Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer.
    Backhus LM; Petasis NA; Uddin J; Schönthal AH; Bart RD; Lin Y; Starnes VA; Bremner RM
    J Thorac Cardiovasc Surg; 2005 Nov; 130(5):1406-12. PubMed ID: 16256796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    J Rheumatol Suppl; 1999 Apr; 56():31-6. PubMed ID: 10225538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells.
    Lim YJ; Rhee JC; Bae YM; Chun WJ
    World J Gastroenterol; 2007 Apr; 13(13):1947-52. PubMed ID: 17461495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer.
    Heslin MJ; Hawkins A; Boedefeld W; Arnoletti JP; Frolov A; Soong R; Urist MM; Bland KI
    Ann Surg; 2005 Jun; 241(6):941-6; discussion 946-7. PubMed ID: 15912043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharma-clinics. The drug of the month. Celecoxib (Celebrex)].
    Scheen AJ
    Rev Med Liege; 2001 Jan; 56(1):53-5. PubMed ID: 11256140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results.
    Tindall E
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S13-7. PubMed ID: 10643176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclooxygenase inhibitors for skin cancer prevention: are they beneficial enough?
    Pentland AP
    Arch Dermatol; 2002 Jun; 138(6):823-4. PubMed ID: 12056966
    [No Abstract]   [Full Text] [Related]  

  • 34. Balancing the risks and benefits of celecoxib.
    Caldwell B; Beasley R; Weatherall M; Metcalfe S
    Am J Med; 2007 Jun; 120(6):e17. PubMed ID: 17524734
    [No Abstract]   [Full Text] [Related]  

  • 35. The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress.
    Hawk E; Viner JL
    Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):185-7. PubMed ID: 17301246
    [No Abstract]   [Full Text] [Related]  

  • 36. Determine whether perioperative celecoxib administration would reduce opioid consumption and provide effective pain relief in patients undergoing arthroscopic knee surgery.
    Ekman EF; Berger M; Bhadra P
    Arthroscopy; 2006 Jul; 22(7):804. PubMed ID: 16843817
    [No Abstract]   [Full Text] [Related]  

  • 37. In vivo effect of celecoxib and tenoxicam on oxidant/ anti-oxidant status of patients with knee osteoarthritis.
    Ozgocmen S; Ardicoglu O; Erdogan H; Fadillioglu E; Gudul H
    Ann Clin Lab Sci; 2005; 35(2):137-43. PubMed ID: 15943176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel therapeutic options bring hope to patients with rheumatic conditions--and to the physicians who treat them.
    Pertusi RM
    J Am Osteopath Assoc; 1999 Jun; 99(6):300-1. PubMed ID: 10405514
    [No Abstract]   [Full Text] [Related]  

  • 39. [Safety of celecoxib administration].
    Babić-Naglić D
    Reumatizam; 2002; 49(2):26-8. PubMed ID: 12476757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Celecoxib enhances the detoxification of diethylnitrosamine in rat liver cancer.
    Salcido-Neyoy ME; Sierra-Santoyo A; Beltrán-Ramírez O; Macías-Pérez JR; Villa-Treviño S
    World J Gastroenterol; 2009 May; 15(19):2345-50. PubMed ID: 19452576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.